Gene and cell therapy group Oxford Biomedica has signed a new Licence and Supply Agreement with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies.
The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica’s LentiVector platform for its application in their lead CAR-T programme, and puts in place a three-year Clinical Supply Agreement.
Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials.
The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of products sold that utilise the company’s LentiVector platform.
Stuart Paynter, Chief Financial Officer of Oxford Biomedica, said: “This new partnership further demonstrates the strength of our LentiVector platform.
“This is another example of our important role in supporting the development of potentially life-saving CAR-T therapies and has been made possible by the fact we’ve been able to offer strategically re-acquired targets to our customers.
“As a leading viral vector specialist, we look forward to continuing to build upon our position as a partner of choice in cell and gene therapy.”